- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01033721
Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration (P52901)
September 20, 2012 updated by: Paloma Pharmaceuticals, Inc.
A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients With Advanced Neovascular Age-Related Macular Degeneration (AMD)
Palomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation.
Palomid 529 will be examined to determine if the safety, tolerability and pharmacokinetic profile of single ascending doses when administered intravitreally or subconjunctivally.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Ophthalmic Consultants of Boston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Best corrected visual acuity in the study eye between 20/100 and 20/800 (between 53 and 4 ETDRS letters read), and better or equal to 20/200 (minimum of 34 letters read) in the fellow eye.
- Subfoveal choroidal neovascularization (CNV) due to AMD
- Total area of the lesion (including blood, neovascularization and scar/atrophy) must be < 12 DA.
- Only 1 eye will be treated in the study. If both eyes are eligible, the investigator will select the eye with the most active CNV
- Clear ocular media and adequate pupillary dilatation to permit good stereo fundus photography for screening
- Intraocular pressure of 21 mm Hg or less
- Retinal thickness ≥ 250 μm by OCT, with presence of intraretinal or subretinal fluid
Exclusion Criteria:
- Any retinovascular disease or retinal degeneration other than AMD
- Serous pigment epithelial detachment without the presence of neovascularization
- Previous posterior vitrectomy or retinal surgery
- Any periocular infection in the past 4 weeks
- Concomitant therapy with anti-VEGF therapies, e.g. Avastin, Lucentis or Macugen, or previous use of these agents within 60 days of screening
- Concomitant therapy with intravenous or intravitreous corticosteroids or use within 90 days of screening
- Significant media opacities, including cataract, which might interfere with visual acuity, assessment of toxicity, or fundus photography
- Cataract surgery in the study eye within 3 months of screening
- Intraocular surgery in the study eye within 3 months of screening
- Presence of ocular infection in the study eye
- Presence of severe myopia (-8 diopters or greater) in the study eye
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety-Review AEs, concomitant meds-Vitals, HR, systolic/diastolic BP, temperature, weight-ECG changes; Physical exam-Laboratory parameters-Ophthalmic exam-visual acuity, IOP, slit lamp fundus exam, fundus photography, fluorescein angiography, OCT
Time Frame: 43 days
|
43 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy-Mean change in visual acuity by ETDRS testing-Decreased leakage and/or size on FA, decreased retinal thickness in OCT-Decreased fibrosis if detectable based on fundus examination, photography, angiography and OCT
Time Frame: 43 days
|
43 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeffrey S. Heier, M.D., Ophthalmic Consultants of Boston
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2010
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
December 15, 2009
First Submitted That Met QC Criteria
December 15, 2009
First Posted (Estimate)
December 16, 2009
Study Record Updates
Last Update Posted (Estimate)
September 24, 2012
Last Update Submitted That Met QC Criteria
September 20, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Paloma P529 Ocular
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-Related Macular Degeneration
-
Novartis PharmaceuticalsActive, not recruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheNot yet recruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn
Clinical Trials on Palomid 529
-
National Eye Institute (NEI)CompletedAge-Related Macular DegenerationUnited States
-
YourChoice Therapeutics, Inc.RecruitingMale ContraceptionUnited Kingdom
-
Immuron Ltd.TerminatedClostridium Difficile Infection | Clostridium Difficile Infection RecurrenceIsrael
-
National Cancer Institute (NCI)CompletedNeuroblastoma | Rhabdomyosarcoma | Ewing's SarcomaUnited States
-
Leiden University Medical CenterNovo Nordisk A/SCompletedCardiovascular Disease | Fatty Liver | Metabolic Syndrome | Diabetes Mellitus Type 2 | Diastolic DysfunctionNetherlands
-
Leiden University Medical CenterNovo Nordisk A/SCompletedCardiovascular Disease | Fatty Liver | Metabolic Syndrome | Diabetes Mellitus Type 2 | Diastolic DysfunctionNetherlands
-
Children's Oncology GroupNational Cancer Institute (NCI); Children's Cancer GroupCompletedLymphoma | Cardiac ToxicityUnited States, Australia, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedSarcoma | Cardiac ToxicityUnited States, Canada, Netherlands, Puerto Rico, Switzerland, Australia
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLymphoma | Cardiac ToxicityUnited States, Canada, Switzerland